Alkermes, Anavex Life Sciences ClinicalTrials.gov Study Record Detail For Co.’s ‘Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers,’ Shows Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT04928703
Vyne Therapeutics ClinicalTrials.gov Study Record Detail For Co.’s ‘Efficacy and Safety of FMX114 Versus Vehicle in Adults With Atopic Dermatitis,’ Shows Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT04927572
Anavex Life Sciences, Alkermes Post Study Titled ‘Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers’ To ClinicalTrials.Gov Site
https://clinicaltrials.gov/ct2/show/NCT04928703
Altimmune’s Stock Trades In A Double Bottom Pattern: What’s Next?
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was achieved at six weeks with a weekly dose of 1.8mg.
Natera Highlights Publication Of Prospective, Randomized Study Validating Signatera For Prediction Of Immunotherapy Benefit In Nature Journal
Natera,Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ability of its personalized and tumor-informed
Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients
Aprea Therapeutics Inc (NASDAQ:APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the…
Mallinckrodt Wins FDA Approval For Its Regenerative Skin Burn Graft
Following four months of regulatory delays amid the COVID-19 pandemic, the FDA has finally approved Mallinckrodt Plc’s (OTC:MNKKQ) regenerative tissue graft…
Yield10 Bioscience To Present On Advances Using Camelina Platform To Produce PHA Bioplastic At 2021 Synthetic Biology Virtual Conference
Yield10 Bioscience, Inc. (NASDAQ:YTEN), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the 2021 Synthetic Biology: Engineering, Evolution &
Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial
The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ:PSTV) to proceed to the eighth cohort of Phase 1…